Comparing injecting and non-injecting illicit opioid users in a multisite Canadian sample (OPICAN cohort)

European Addiction Research

Volumn 12, Issue 4, 2006, Pages 230-239

  Fischer, Benedikt ^a   Manzoni, Patrik ^a   Rehm, Jürgen ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Drug culture; Drug market; Opioid use; Route of administration

Indexed keywords

ALCOHOL; BENZODIAZEPINE; COCAINE; CODEINE; DIAMORPHINE; HYDROMORPHONE; ILLICIT DRUG; OPIATE;

ADULT; ARTICLE; CANADA; CONTROLLED STUDY; DRUG USE; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; MENTAL DISEASE; MORBIDITY; MORTALITY; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SOCIOECONOMICS;

ADULT; ANALGESICS, OPIOID; CANADA; COHORT STUDIES; FEMALE; HEPATITIS C; HIV INFECTIONS; HUMANS; MALE; OVERDOSE; STREET DRUGS; SUBSTANCE ABUSE, INTRAVENOUS; SUBSTANCE-RELATED DISORDERS;

EID: 33748652449     PISSN: 10226877     EISSN: None     Source Type: Journal    
DOI: 10.1159/000094425     Document Type: Article

References (68)

1. European Monitoring Centre for Drugs and Drug Addiction: European report on drug consumption rooms. Luxembourg, Office for Official Publications of the European Communities, 2004.
2. Woolf CJ, Hashmi M: Use and abuse of opioid analgesics: Potential methods to prevent and deter non-medical consumption of prescription opioids. Curr Opin Investig Drugs 2004;5:61-66.
3. Cowan DT, Allan LG, Libretto SE, Griffiths P: Opioid drugs: a comparative survey of therapeutic and 'street' use. Pain Med 2001;2:193-203.
4. Grund J-P: From the straw to the needle? Determinants of heroin administration routes; in Inciardi J, Harrison L (eds): Heroin in the Age of Crack-Cocaine. London, Sage, 1998, pp 215-258.
5. Strang J, Griffiths P, Powis B, Gossop M: First use of heroin: changes in the route of administration over time. BMJ 1992;304:1222-1223.
6. Smyth B, O'Brien M, Barry J: Trends in treated opiate misuse in Dublin: the emergence of chasing the dragon. Addiction 2000;95:1217-1223.
7. Chitwood DD, Comerford M, Sanchez J: Prevalence and risk factors for HIV among sniffers, short-term injectors, and long-term injectors of heroin. J Psychoactive Drugs 2003;35:445-453.
8. de la Fuente L, Barrio G, Royuela L, Bravo MJ: The transition from injecting to smoking heroin in three Spanish cities. The Spanish Group for the Study of the Route of Heroin Administration. Addiction 1997;92:1749-1763.
9. van Ameijden E, Coutinho R: Large decline in injecting drug use in Amsterdam, 1986-1998: explanatory mechanisms and determinants of injecting transitions. J Epidemiol Community Health 2001;55:356-363.
10. Sotheran JL, Goldsmith DS, Blasco M, Friedman SR: Heroin sniffing as self-regulation among injecting and non-injecting heroin users. J Drug Issues 1999;29:401-422.
11. Neaigus A, Miller M, Friedman S, et al: Potential risk factors for the transition to injection among non-injecting heroin users: a comparison of former injectors and never injectors. Addiction 2001;96:847-860.
12. Griffiths P, Gossop M, Powis B, Strang J: Transitions in patterns of heroin administration: a study of heroin chasers and heroin injectors. Addiction 1994;89:301-309.
13. Fischer B, Rehm J, Brissette S, et al: Illicit opioid use in Canada: comparing social, health and drug use characteristics of untreated users in five cities (OPICAN study). J Urban Health 2005;82:250-266.
14. Strang J, Griffiths P, Powis B, Gossop M: Heroin chasers and heroin injectors: differences observed in a community sample in London, UK. Am J Addict 1999;8:148-160.
15. Stohler R, Dursteler-MacFarland K, Gramespacher C, Petitjean S, Battegay R, Ladewig D: A comparison of heroin chasers with heroin injectors in Switzerland. Eur Addict Res 2000;6:154-159.
16. Quaglio G, Lugoboni F, Pajusco B, et al: Factors associated with hepatitis C virus infection in injection and non-injection drug users in Italy. Clin Infect Dis 2003;37:33-40.
17. Bravo MJ, Barrio G, de la Fuente L, Royuela L, Domingo L, Silva T: Reasons for selecting an initial route of heroin administration and for subsequent transitions during a severe HIV epidemic. Addiction 2003;98:749-760.
18. Strang J, Griffiths P, Powis B, Abbey J, Gossop M: How constant is an individual's route of heroin administration? Data from treatment and non-treatment samples. Drug Alcohol Depend 1997;46:115-118.
19. Swift W, Maher L, Sunjic S: Transitions between routes of heroin administration: a study of Caucasian and Indochinese heroin users in south-western Sydney, Australia. Addiction 1999;94:71-82.
20. Strang J, Griffiths P, Gossop M: Heroin smoking by 'chasing the dragon': origins and history. Addiction 1997;92:673-683.
21. Gossop M, Marsden J, Stewart D: Treatment outcomes of stimulant misusers: one year follow-up results from the National Treatment Outcome Research Study (NTORS). Addict Behav 2000;25:509-522.
22. de la Fuente L, Saavedra P, Barrio G, Royuela L, Vicente J: Temporal and geographic variations in the characteristics of heroin seized in Spain and their relation with the route of administration. Spanish Group for the Study of the Purity of Seized Drugs. Drug Alcohol Depend 1996;40:185-194.
23. Andersen HS, Sestoft D, Lillebaek T, Gabrielsen G, Hemmingsen R: Heroin dependence: consequences and precursors related to route of administration. Nord J Psychiatry 1999;53:153-158.
24. McCoy CB, Metsch LR, Chitwood DD, Miles C: Drug use and barriers to use of health care services. Subst Use Misuse 2001;36:789-806.
25. Gossop M, Darke S, Griffiths P, et al: The severity of dependence scale (SDS): psychometric properties of the SDS in English and Australian samples of heroin, cocaine and amphetamine users. Addiction 1995;90:607-614.
26. Smolka M, Schmidt LG: The influence of heroin dose and route of administration on the severity of the opiate withdrawal syndrome. Addiction 1999;94:1191-1198.
27. Gossop M, Griffiths P, Powis B, Strang J: Severity of dependence and route of administration of heroin, cocaine and amphetamines. Br J Addict 1992;87:1527-1536.
28. Latkin C, Knowlton A, Sherman S: Routes of drug administration, differential affiliation, and lifestyle stability among cocaine and opiate users: implications to HIV prevention. J Subst Abuse 2001;13:89-102.
29. Barrio G, De la Fuente L, Royuela L, Diaz A, Rodriguez-Artalejo F: Cocaine use among heroin users in Spain: the diffusion of crack and cocaine smoking. Spanish Group for the Study on the Route of Administration of Drugs. J Epidemiol Community Health 1998;52:172-180.
30. Dinwiddie SH, Cottler L, Compton W, Abdallah AB: Psychopathology and HIV risk behaviors among injection drug users in and out of treatment. Drug Alcohol Depend 1996;43:1-11.
31. Razak MH, Jittiwutikarn J, Suriyanon V, et al: HIV prevalence and risks among injection and noninjection drug users in northern Thailand: need for comprehensive HIV prevention programs. J Acquir Immune Defic Syndr 2003;33:259-266.
32. Gyarmathy V, Neaigus A, Miller M, Friedman S, Des Jarlais D: Risk correlates of prevalent HIV, hepatitis B virus, and hepatitis C virus infections among non-injecting heroin users. J Acquir Immune Defic Syndr 2002;30:448-456.
33. Koblin BA, Factor SH, Wu Y, Vlahov D: Hepatitis C virus infection among non-injecting drug users in New York City. J Med Virol 2003;70:387-390.
34. Fischer B, Remis R, Haydon E: Hepatitis C, illegale Drogen und marginalisierte Populationen in Kanada: Ein kurzer Überblick zu Epidemiologie, Prävention und Behandlung; in Stover H (ed): Tagungsband zum 1. Internationalen Fachtag zu Hepatitis C. Berlin, Akzept e.V., 2004, pp 131-144.
35. Tortu S, McMahon J, Pouget E, Hamid R: Sharing of noninjection drug-use implements as a risk factor for Hepatitis C. Subst Use Misuse 2004;39:211-224.
36. Health Canada: Reducing the harm associated with injecting drug use in Canada. Ottawa, Federal/Provincial/Territorial Committee on Injection Drug Use, 2001.
37. Remis R, Leclerc P, Routledge R, et al: Consortium to characterize injection drug users in Canada (Montreal, Toronto and Vancouver) Final Report. Toronto, self-published, 1998.
38. Fischer B, Vasdev S, Haydon E, Baliunas D, Rehm J: Willingness for hepatitis C treatment in a sample of injection drug users in Toronto, Canada (in French). Presse Med 2005;34:1209-1212.
39. Monga N, Rehm J, Fischer B, et al: Using latent class analysis (LCA) to analyze patterns of drug use in a population of illicit opioid users. 2006, under review.
40. Kennedy J: Analyzing qualitative data: introductory log-linear analysis for behavioral research. New York, Praeger, 1983.
41. Strang J, Gossop M: Heroin prescribing in the British system: historical review. Eur Addict Res 1996;2:185-193.
42. Tyndall MW, Braneau J, Brogly S, Spittal P: Satellite needle distribution among injection drug users: policy and practice in two Canadian cities. J Acquir Immune Defic Syndr 2002;31:98-105.
43. Spittal PM, Bruneau J, Craib KJ, et al: Surviving the sex trade: a comparison of HIV risk behaviours among street-involved women in two Canadian cities who inject drugs. Aids Care 2003;15:187-195.
44. Morissette C, Roy E, Parent R, Alary M, and the SurvUDI Group: Temporal trends in HIV incidence and risk behaviours among IDUs in the SurvUDI study 1995-2002 (abstract). Can J Infect Dis 2004;15(suppl A):49A.
45. Health Canada: I-Track: enhanced surveillance of risk behaviours among injecting drug users in Canada (pilot survey report). Ottawa, Surveillance and Risk Assessment Division, Centre for Infectious Disease Prevention and Control, Population and Public Health Branch, 2004.
46. Galea S, Vlahov D: Social determinants and the health of drug users: Socioeconomic status, homelessness, and incarceration. Public Health Rep 2002;117(suppl 1):S135-S145.
47. Palepu A, Strathdee SA, Hogg RS, et al: The social determinants of emergency department and hospital use by injection drug users in Canada. J Urban Health 1999;76:409-418.
48. O'Driscoll P, McGough J, Hagan H, Thiede H, Critchlow C, Alexander E: Predictors of accidental fatal drug overdose among a cohort of injection drug users. Am J Public Health 2001;91:984-987.
49. Fischer B, Brissette S, Brochu S, et al: Prevalence and determinants of overdose incidents among illicit opioid users in five cities across Canada. Can Med Assoc J 2004;171:235-239.
50. Sibthorpe B, Lear B: Circumstances surrounding needle use transitions among injection drug users: implications for HIV intervention. Int J Addict 1994;29:1245-1257.
51. Galai N, Safaeian M, Vlahov D, Bolotin A, Celentano DD: Longitudinal patterns of drug injection behavior in the ALIVE Study Cohort, 1988-2000: description and determinants. Am J Epidemiol 2003;158:695-704.
52. Crofts N, Louie R, Rosenthal D, Jolley D: The first fit: circumstances surrounding initiation into injecting. Addiction 1996;91:1187-1196.
53. Vlahov D, Junge B: The role of needle exchange programs in HIV prevention. Public Health Rep 1998;113(suppl 1):75-80.
54. Hankins C: Syringe exchange in Canada: good but not enough to stem the HIV tide. Subst Use Misuse 1998;33:1129-1145.
55. Strathdee SA, Patrick DM, Currie SL, et al: Needle exchange is not enough: lessons from the Vancouver injecting drug use study. AIDS 1997;11:F59-F65.
56. Fischer B, Rehm J, Blitz-Miller T: Injection drug use and preventive measures: a comparison of Canadian and Western European jurisdictions over time. Can Med Assoc J 2000;162:1709-1713.
57. Rehm J, Fischer B, Haydon E: Reducing the risks, harms and costs of HIV/AIDS and injection drug use: a synthesis of the evidence base for development of policies and programs. Warsaw, Health Canada/UNAIDS/Canadian International Development Agency, 2003.
58. Kerr T, Wood E, Small D, Palepu A, Tyndall M: Potential use of safer injection facilities among injection drug users in Vancouver's downtown eastside. Can Med Assoc J 2003;169:759-763.
59. Best D, Harris J, Gossop M, et al: Use of nonprescribed methadone and other illicit drugs during methadone maintenance treatment. Drug Alcohol Rev 2000;19:9-16.
60. Magura S, Kang S-Y, Nwakeze P, Demsky S: Temporal patterns of heroin and cocaine use among methadone patients. Subst Use Misuse 1998;33:2441-2467.
61. Fischer B, Rehm J, Kim G, Kirst M: Eyes wide shut? A conceptual and empirical critique of methadone maintenance treatment. Eur Addict Res 2005;11:1-12.
62. Hunt N, Griffiths P, Southwell M, Stillwell G, Strang J: Preventing and curtailing injecting drug use: a review of opportunities for developing and delivering 'route transition interventions'. Drug Alcohol Rev 1999;18:441-451.
63. Casriel C, Des Jarlais DC, Rodriguez R, Friedman SR, Stephenson B, Khuri E: Working with heroin sniffers: clinical issues in preventing drug injection. J Subst Abuse Treat 1990;7:1-10.
64. Hunt N, Stillwell G, Taylor C, Griffiths P: Evaluation of a brief intervention to prevent initiation into injecting drugs. Drugs Educ, Prev Policy 1998;5:185-194.
65. Des Jarlais D, Casriel C, Friedman S, Rosenblum A: AIDS and the transition to illicit drug injection - results of a randomized trial prevention program. Br J Addict 1992;87:493-498.
66. Eland-Goossensen MA, Van de Goor LAM, Vollemans EC, Hendriks VM, Garretsen HFL: Snowball sampling applied to opiate addicts outside the treatment system. Addict Res 1997;5:317-330.
67. Harrison L: The validity of self-reported data on drug use. J Drug Issues 1995;25:91-111.
68. Anglin MD, Hser YI, Chou C: Reliability and validity of retrospective behavioral self-report by narcotics addicts. Eval Rev 1993;17:91-108.